Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Net Cash Flow (2016 - 2025)

Cytokinetics (CYTK) has disclosed Net Cash Flow for 16 consecutive years, with $97.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow changed N/A to $97.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $76.3 million, a N/A change, with the full-year FY2025 number at $31.1 million, up 269.32% from a year prior.
  • Net Cash Flow was $97.2 million for Q4 2025 at Cytokinetics, up from -$20.9 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $97.2 million in Q4 2025 to a low of -$143.1 million in Q3 2024.
  • A 5-year average of $2.4 million and a median of $6.9 million in 2024 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: surged 1207.47% in 2023, then tumbled 560.92% in 2024.
  • Cytokinetics' Net Cash Flow stood at $22.1 million in 2021, then crashed by 276.69% to -$39.1 million in 2022, then soared by 134.19% to $13.4 million in 2023, then crashed by 1171.96% to -$143.1 million in 2024, then surged by 167.89% to $97.2 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Net Cash Flow are $97.2 million (Q4 2025), -$20.9 million (Q1 2025), and -$143.1 million (Q3 2024).